非小细胞肺癌血内皮干细胞检测及临床意义

目的探讨化疗对非小细胞肺癌（NSCLC）患者血内皮干细胞（cEPCs）的影响。方法51例晚期NSCLC患者紫杉醇联合顺铂化疗过程中，分别于化疗前1d、化疗开始后第7天、第15天和第42天用流式细胞仪检测外周血cEPCs数量。cEPCs的分子标志物定义为cD34＋／cDl33＋／vEGFR-2＋。结果化疗周期的不同时间点外周血cEPCs数量存在差异。化疗后第15天cEPCs最多（F=5．153，P=0．002），化疗获益者化疗后cEPCs减少（t=3．716，P〈0．001），疾病进展者cEPCs增加（t=-4．215，P〈0．001），cEPCs数量变化与化疗疗效相关（r=0．708，P〈0．001）。化疗获益者治疗前的cEPCs数量低于化疗无效者（t=5．081，P〈0．001）。结论NSCLC的化疗疗效与cEPCs数量密切相关；监测非小细胞肺癌患者的cEPCs有可能作为一种新的判断预后的指标。

Objective To probe into the effects of chemotherapy on the circulating endothelial progenitor cells （ cEPCs ） in patients with non-small cell lung caner （ NSCLC ） . Methods The number of the peripheral blood cEPCs was determined through the flow cytometer 1 day before chemotherapy, as well as on the 7th, 15th, and 42nd days after starting the chemotherapy in the 51 cases of patients with advanced NSCLC that received paclitaxel combined with cisplatin chemotherapy. The definition of the molecular marker of cEPCs was CD34＋/CD133＋/VEGFR-2＋. Results The number of the peripheral blood cEPCs at various time points during the chemotherapy cycle showed difference. The number of cEPCs reached a peak on the 15th day after chemotherapy （ F=5.153, P=0.002 ） , that reduced in chemotherapy beneficiaries after chemotherapy （ t=3.716, P〈0.001 ） , and that increased in those with disease progression （ t=4.215, P〈0.001 ） ; and the change of the number of cEPCs was related to the therapeutic effect of chemotherapy （ r=0.708, P〈0.001 ） . The number of cEPCs before treatment was lower in chemotherapy beneficiaries than in those who did not react to chemotherapy （ t=5.081, P〈0.001 ） . Conclusion The therapeutic effect of chemotherapy on NSCLC was closely correlated with the number of cEPCs, and monitoring the cEPCs in patients with NSCLC might be served as a novel indicator for judging the prognosis.